Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Clin Res Cardiol ; 112(8): 1087-1095, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36964794

ABSTRACT

OBJECTIVES: Renal venous congestion due to backward heart failure leads to disturbance of renal function in acute decompensated heart failure (ADHF). Whether decongestion strategies have an impact on renal venous congestion is unknown. Objective was to evaluate changes in intrarenal hemodynamics using intrarenal Doppler ultrasonography (IRD) in patients with heart failure with reduced ejection fraction (HFrEF) and ADHF undergoing recompensation. METHODS: Prospective observational study in patients with left ventricular ejection fraction (LV-EF) ≤ 35% hospitalized due to ADHF. IRD measurement was performed within the first 48 h of hospitalisation and before discharge. Decongestion strategies were based on clinical judgement according to heart failure guidelines. IRD was used to assess intrarenal venous flow (IRVF) pattern, venous impedance index (VII) and resistance index (RI). Laboratory analyses included plasma creatinine, eGFR and albuminuria. RESULTS: A number of 35 patients with ADHF and LV-EF ≤ 35% were included into the study. IRD could be performed in 30 patients at inclusion and discharge. At discharge, there was a significant reduction of VII from a median of 1.0 (0.86-1.0) to 0.59 (0.26-1.0) (p < 0.01) as well as improvement of IRVF pattern categories (p < 0.05) compared to inclusion. Albuminuria was significantly reduced from a median of 78 mg/g creatinine (39-238) to 29 mg/g creatinine (16-127) (p = 0.02) and proportion of patients with normoalbuminuria increased (p = 0.01). Plasma creatinine and RI remained unchanged (p = 0.73; p = 0.43). DISCUSSION: This is the first study showing an effect of standard ADHF therapy on parameters of renal venous congestion in patients with HFrEF and ADHF. Doppler sonographic evaluation of renal venous congestion might provide additional information to guide decongestion strategies in patients with ADHF.


Subject(s)
Heart Failure , Hyperemia , Ventricular Dysfunction, Left , Humans , Heart Failure/diagnostic imaging , Stroke Volume , Albuminuria , Creatinine , Ventricular Function, Left , Ultrasonography, Doppler
2.
Eur J Pharm Biopharm ; 167: 1-8, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34273543

ABSTRACT

BACKGROUND: Despite the increasing prevalence and medical burden of obesity, the understanding of gastrointestinal physiology in obesity is scarce, which hampers drug development. AIM: To investigate the effect of obesity and food intake on gastrointestinal transit, pressure and pH. MATERIAL AND METHODS: An exploratory cross-sectional study using a wireless motility capsule (SmartPill©) was performed in 11 participants with obesity and 11 age- and gender-matched participants with normal weight (group) in fasted and fed state (visit). During the first visit, the capsule was ingested after an overnight fast. During a second visit, the capsule was ingested after a nutritional drink to simulate fed state. Linear mixed models were constructed to compare segmental gastrointestinal transit, pressure and pH between groups (obesity or control) and within every group (fasted or fed). RESULTS: Food intake slowed gastric emptying in both groups (both P < 0.0001), though food-induced gastric contractility was higher in participants with obesity compared to controls (P = 0.02). In the small intestine, a higher contractility (P = 0.001), shorter transit (P = 0.04) and lower median pH (P = 0.002) was observed in participants with obesity compared to controls. No differences were observed for colonic measurements. CONCLUSION: Obesity has a profound impact on gastrointestinal physiology, which should be taken into account for drug development.


Subject(s)
Gastric Emptying/physiology , Gastrointestinal Motility/physiology , Gastrointestinal Transit/physiology , Obesity/complications , Adolescent , Adult , Capsules , Cross-Sectional Studies , Eating , Female , Humans , Hydrogen-Ion Concentration , Male , Middle Aged , Young Adult
3.
Internist (Berl) ; 60(6): 578-586, 2019 Jun.
Article in German | MEDLINE | ID: mdl-31001671

ABSTRACT

In addition to the early detection of an acute kidney injury (AKI), several problems or questions have to be addressed. These include the identification of the etiology, the severity (functional or structural), the prognosis (recovery or transition to chronic renal failure), the course of the disease (dialysis or not), and the identification of specific treatment options for AKI. The following article provides an overview of established and new AKI biomarkers as well as an outlook on the potential of future biomarker-associated models of AKI.


Subject(s)
Acute Kidney Injury/blood , Acute Kidney Injury/urine , Biomarkers/blood , Biomarkers/urine , Acute Kidney Injury/therapy , Creatinine , Humans , Renal Dialysis , Renal Insufficiency, Chronic/complications
4.
Internist (Berl) ; 59(10): 1011-1020, 2018 Oct.
Article in German | MEDLINE | ID: mdl-30182192

ABSTRACT

Baroreflex activation therapy (BAT) is a sympathoinhibitory procedure for treatment of therapy-resistant hypertension (rsHTN) and severe heart failure with reduced ejection fraction (HFrEF) that been available for several years. The double-blind, randomized Rheos Pivotal Trial demonstrated a blood pressure lowering effect in patients with rsHTN for the first-generation BAT device. A smaller randomized study in heart failure showed that the Barostim Neo system is safe and can improve heart failure symptoms and decrease neuroendocrine activation. However, for this unilateral system, which is currently in clinical use, no data from large randomized trials exist. Despite existing data for BAT in rsHTN and HFrEF, large randomized trials, showing reduction of blood pressure and cardiovascular events are still lacking. Therefore, BAT's efficacy and safety cannot be conclusively assessed.


Subject(s)
Baroreflex/physiology , Blood Pressure/physiology , Electric Stimulation Therapy/methods , Heart Failure/therapy , Hypertension/therapy , Electric Stimulation Therapy/adverse effects , Electrodes, Implanted/adverse effects , Humans , Hypertension/physiopathology , Randomized Controlled Trials as Topic , Stroke Volume
5.
Internist (Berl) ; 59(6): 567-579, 2018 06.
Article in German | MEDLINE | ID: mdl-29721584

ABSTRACT

Therapy-resistant and therapy-refractory arterial hypertension differ in prevalence, pathogenesis, prognosis and therapy. In both cases, a structured approach is required, with the exclusion of pseudoresistance and, subsequently, secondary hypertension. Resistant hypertension has been reported to be more responsive to intensified diuretic therapy, whereas refractory hypertension is presumed to require sympathoinhibitory therapy. Once the general measures and the drug-based step-up therapy have been exhausted, interventional procedures are available.


Subject(s)
Antihypertensive Agents , Hypertension , Antihypertensive Agents/therapeutic use , Drug Resistance , Humans , Hypertension/drug therapy
6.
Internist (Berl) ; 59(5): 420-427, 2018 May.
Article in German | MEDLINE | ID: mdl-29594438

ABSTRACT

Heart failure and kidney dysfunction are common comorbidities with overlapping and synergizing mechanisms. Coincidence of both pathologies aggravates disease progression rates, symptoms, and outcomes. The treatment of patients with advanced renal insufficiency is faced with limited evidence for therapies that are standard of care in patients with normal and moderate kidney failure, frequent deterioration of kidney function during therapy, and onset of hyperkalemia, which pose challenges for clinical care, requiring intensified physician-patient contacts. A special challenge is the so-called diuretic resistance, which may require extracorporeal drainage.


Subject(s)
Heart Failure , Renal Insufficiency , Diuretics , Heart Failure/complications , Humans , Kidney , Renal Insufficiency/complications
7.
Internist (Berl) ; 58(10): 1114-1123, 2017 Oct.
Article in German | MEDLINE | ID: mdl-28835975

ABSTRACT

Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.


Subject(s)
Baroreflex/physiology , Coronary Vasospasm/physiopathology , Coronary Vasospasm/therapy , Electric Stimulation Therapy/methods , Hypertension/physiopathology , Hypertension/therapy , Blood Pressure/physiology , Carotid Sinus/physiopathology , Electric Stimulation Therapy/instrumentation , Electrodes, Implanted , Equipment Design , Heart Rate/physiology , Parasympathetic Nervous System/physiopathology , Sympathetic Nervous System/physiopathology
8.
J Control Release ; 220(Pt A): 71-78, 2015 Dec 28.
Article in English | MEDLINE | ID: mdl-26476174

ABSTRACT

The intraluminal conditions of the fed stomach are critical for drug release from solid oral dosage forms and thus, often associated with the occurrence of food effects on oral bioavailability. In this study, intragastric pH and pressure profiles present after the ingestion of the high-caloric, high-fat (964 kcal) FDA standard breakfast were investigated in 19 healthy human subjects by using the telemetric SmartPill® capsule system (26 × 13 mm). Since the gastric emptying of such large non-digestible objects is typically accomplished by the migrating motor complex phase III activity, the time required for recurrence of fasted state motility determined the gastric emptying time (GET). Following the diet recommendations of the FDA guidance on food effect studies, the mean GET of the telemetric motility capsule was 15.3 ± 4.7 h. Thus, the high caloric value of the standard breakfast impeded gastric emptying before lunch in 18 out of 19 subjects. During its gastric transit, the capsule was exposed to highly dynamic conditions in terms of pH and pressure, which were mainly dependent on further meal and liquid intake, as well as the intragastric capsule deposition behavior. Maximum pH values in the stomach were measured immediately after capsule intake. The median pH value of the 5 min period after capsule ingestion ranged between pH 3.3 and 5.3. Subsequently, the pH decreased relatively constantly and reached minimum values of pH 0-1 after approximately 4 h. The maximum pressure within the stomach amounted to 293 ± 109 mbar and was clearly higher than the maximum pressure measured at the ileocaecal junction (60 ± 35 mbar). The physiological data on the intraluminal conditions within the fed stomach generated in this study will hopefully contribute to a better understanding of food effects on oral drug product performance.


Subject(s)
Diet, High-Fat , Energy Intake , Gastric Acidity Determination , Gastric Emptying/physiology , Adult , Body Temperature , Female , Gastrointestinal Transit , Humans , Male , Myoelectric Complex, Migrating/physiology , Pressure
9.
Eur J Pharm Sci ; 77: 246-53, 2015 Sep 18.
Article in English | MEDLINE | ID: mdl-26093053

ABSTRACT

The objective of this study was to investigate the suitability of "Eudragit® RL/Eudragit® L55" (RL/L55) blend coatings for a pH-independent release of acidic drugs. A coating for ketoprofen and naproxen mini tablets was developed showing constant drug release rate under pharmacopeial two-stage test conditions for at least 300 min. To simulate drug release from the mini tablets coated with RL/L55 blends in the gastrointestinal (GI) tract, drug release profiles in Hanks buffer pH 6.8 were recorded and compared with drug release profiles in compendial media. RL/L55 blend coatings showed increased drug permeability in Hanks buffer pH 6.8 compared to phosphate buffer pH 6.8 due to its higher ion concentration. However, drug release rates of acidic drugs were lower in Hanks buffer pH 6.8 because of the lower buffer capacity resulting in reduced drug solubility. Further dissolution tests were performed in Hanks buffer using pH sequences simulating the physiological pH conditions in the GI tract. Drug release from mini tablets coated with an RL/L55 blend (8:1) was insensitive to pH changes of the medium within the pH range of 5.8-7.5. It was concluded that coatings of RL/L55 blends show a high potential for application in coated oral drug delivery systems with a special focus on pH-independent release of acidic drugs.


Subject(s)
Acids/chemistry , Bicarbonates/chemistry , Pharmaceutical Preparations/administration & dosage , Polymers/chemistry , Tablets , Buffers , Solubility
10.
Horm Metab Res ; 47(9): 662-7, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25970792

ABSTRACT

Adrenal tumors, discovered incidentally in approximately 4.5% of imaging procedures, are known as adrenal incidentalomas. Nonclassic congenital adrenal hyperplasia, mild form of 21-hydroxylase deficiency, may lead to the development of adrenocortical tumors. The aim of the study was to evaluate prevalence of the most common nonclassic mutations of CYP21A2 gene in patients with adrenal incidentalomas and investigate possible relationship with clinical outcome. One hundred adult patients with such lesions were enrolled. Clinical, imaging and biochemical evaluation were performed to rule out hormonal overproduction or potential malignancy. All subjects and a control group of 100 neonates were genotyped for P30L, P453S, and V281L mutations of CYP21A2 gene using direct sequencing. Clinical and imaging features as well as hormone levels were analyzed. Heterozygous CYP21A2 gene mutations were detected in 8 subjects but not in the neonates. Thus, the risk of carrying mutant allele was significantly higher in subjects with adrenal tumors (OR=8.7; 95% CI=2.23-389.56; p=0.003). Mean concentrations of renin, basal, and stimulated 17-hydroxyprogesterone were higher and ACTH was lower in the carriers than in the remaining subjects. Furthermore, the carriers had higher incidence of hypertension (100 vs. 52.1%, p=0.008) and diabetes (50 vs. 11.9%, p=0.003). ACTH-stimulated 17-hydroxyprogesterone levels varied widely among the carriers. In summary, prevalence of P30L, P453S, and V281L mutations of CYP21A2 gene is increased in patients with adrenocortical tumors. In these subjects, carrying the analyzed mutant alleles may increase the risk of diabetes and hypertension. ACTH-stimulation test does not satisfactorily predict presence of heterozygous CYP21A2 mutations in patients with adrenal tumors.


Subject(s)
Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/genetics , Steroid 21-Hydroxylase/genetics , 17-alpha-Hydroxyprogesterone/blood , Adolescent , Adrenal Gland Neoplasms/epidemiology , Adult , Aged , Comorbidity , Diabetes Mellitus/epidemiology , Diabetes Mellitus/genetics , Female , Heterozygote , Humans , Hypertension/epidemiology , Hypertension/genetics , Infant, Newborn , Male , Middle Aged , Mutation , Prevalence , Young Adult
11.
Lupus ; 22(14): 1523-5, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24014569

ABSTRACT

We report the case of a 19-year-old woman with progressive proliferative lupus nephritis (LN) class III after induction and maintenance therapy with mycophenolate mofetil (MMF). Despite a satisfying clinical improvement proteinuria progressed under this medication. We treated the patient with additional belimumab after discussing other options. Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. Belimumab might hold promise for this indication.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Immunosuppressive Agents/therapeutic use , Lupus Nephritis/drug therapy , Disease Progression , Female , Humans , Lupus Nephritis/physiopathology , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Proteinuria/drug therapy , Proteinuria/etiology , Remission Induction , Treatment Outcome , Young Adult
12.
Transplant Proc ; 45(1): 142-7, 2013.
Article in English | MEDLINE | ID: mdl-23375288

ABSTRACT

BACKGROUND: The most common immunosuppressive regimens after renal transplantation include calcineurin inhibitors (CNI). However, due to renal toxicity long-term graft survival does not seem to be positively affected by CNIs. METHODS: In the present study, we investigated 17 patients, in which the CNI immunosuppression was converted to a CNI-free, mycophenolate sodium (MPS) regimen. Conversion was performed due to progressive impairment of the graft function from suspected CNI toxicity. We retrospectively analyzed graft function as well as toxicity and surrogate markers for 4 years before and 4 years after conversion using a repeated-measures mixed model data analysis and/or a paired sample t-test. RESULTS: The mean time point of therapy conversion was 11.2 ± 4.6 years after transplantation. Within 1 month of CNI discontinuation, allograft function improved significantly, remaining at a significant level for 2 years. The estimated glomerular filtration rate increased from 43.4 ± 14.8 to a maximum of 55.7 ± 21.7 mL/min at 1 year after conversion (P = .0027). After 4 years, the end of the observation period, renal function was similar to the baseline. There were no significant side effects. CONCLUSION: These data suggested that, when chronic CNI-toxicity is suspected, renal allograft recipients may benefit from CNI withdrawal in favor of a MPS-including immunosuppressive regimen.


Subject(s)
Calcineurin Inhibitors , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/drug therapy , Kidney Transplantation/methods , Mycophenolic Acid/analogs & derivatives , Adult , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Survival , Humans , Kidney/physiopathology , Kidney Failure, Chronic/surgery , Male , Middle Aged , Mycophenolic Acid/therapeutic use , Retrospective Studies , Time Factors , Transplantation, Homologous , Treatment Outcome
13.
Internist (Berl) ; 53(7): 869-73, 2012 Jul.
Article in German | MEDLINE | ID: mdl-22484921

ABSTRACT

Sarcoidosis is a multi-systemic disease. A 21-year-old female patient was admitted to our department with lymphadenopathy, B symptoms, erythema nodosum and joint pain. Sarcoidosis showed a very atypical course, lacking any pulmonary symptoms or typical laboratory values. The diagnosis was finally confirmed histologically and thus various differential diagnoses such as microbiological and malignant diseases could be excluded. Oral steroid medication led to remission.


Subject(s)
Lymphatic Diseases/diagnosis , Lymphatic Diseases/etiology , Sarcoidosis/complications , Sarcoidosis/diagnosis , Steroids/administration & dosage , Administration, Oral , Adult , Analgesics/administration & dosage , Female , Humans , Lymphatic Diseases/drug therapy , Sarcoidosis/drug therapy , Treatment Outcome
14.
Transplant Proc ; 42(9): 3880-2, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21094876

ABSTRACT

In inflammatory bowel disease refractory to established therapies, treatment with biological agents such as monoclonal tumor necrosis factor-α antibodies is an established therapeutic option. However, application in renal allograft recipients is either not licensed or has not yet been systematically examined. Herein, we present 2 case reports of renal allograft recipients who had steroid-refractory ulcerative colitis who demonstrated improvement of symptoms after treatment with infliximab, without signs of effect on transplant function. In both patients, stool frequency decreased significantly. Colonoscopy controls and histologic examination after initiation of treatment revealed a state of remission. Renal function parameters and drug concentrations remained constant.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Colitis, Ulcerative/drug therapy , Drug Resistance , Immunosuppressive Agents/therapeutic use , Kidney Diseases/surgery , Kidney Transplantation , Steroids/therapeutic use , Adult , Colitis, Ulcerative/complications , Colitis, Ulcerative/diagnosis , Colonoscopy , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/adverse effects , Infliximab , Kidney Diseases/complications , Male , Middle Aged , Transplantation, Homologous , Treatment Outcome
15.
Mini Rev Med Chem ; 9(10): 1215-28, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19817712

ABSTRACT

The chemokine CX(3)C-L/FKN is expressed in both soluble and transmembrane/mucin hybrid forms, thus combining chemoattractant functions together with receptor/adhesion molecule properties. In contrast to other chemokine receptors, CX(3)C-R is expressed not only on lymphoid cell populations, but also on several intrinsic cells including tubular epithelial cells and renal fibroblasts where it regulates various aspects of cell viability, matrix synthesis and degradation, migration, inflammation as well as oxidative stress. In the kidney, the chemokines/receptor pair has been shown to play a role in nephrogenesis as well as in the pathogenesis primary and secondary nephropathies. In several animal models and human specimens with acute and chronic renal failure including allograft nephropathy, CX(3)C-L/CX(3)C-R has been shown to exert immune and non-immune mediated renal damages. A blockade of this chemokine system ameliorated acute and chronic renal damages, though the latter to a more robust extent. There seems to a role of the CX(3)C-L/CX(3)C-R pair in mediating acute renal inflammation as well as in progressive chronic renal failure. However, functional studies are lacking for many aspects and further studies are necessary to better define the functional properties of CX(3)C-L/FKN and its receptor.


Subject(s)
Chemokine CX3CL1/genetics , Chemokine CX3CL1/immunology , Kidney Diseases/immunology , Animals , CX3C Chemokine Receptor 1 , Gene Expression Regulation , Humans , Kidney Diseases/pathology , Receptors, Cytokine/genetics , Receptors, Cytokine/immunology , Receptors, HIV/genetics , Receptors, HIV/immunology
16.
Dtsch Med Wochenschr ; 134(34-35): 1681-5, 2009 Aug.
Article in German | MEDLINE | ID: mdl-19707964

ABSTRACT

The occurrence of microalbuminuria or albuminuria indicates a disturbance of the barrier function of endothelial cells, basement membrane or of a structural-renal disease (including diseased podocytes). The prevalence of microalbuminuria in the general population is about 8 %, however, in high risk groups, prevalence rates of 50 % and more have been observed. Its incidence is strongly associated with increased cardiovascular morbidity and mortality. Blood pressure control and the blockade of the renin-angiotensin-aldosteron-system (RAAS), respectively, is the central mechanism to reduce cardio-vascular-renal end points as well as mortality.


Subject(s)
Albuminuria/diagnosis , Albuminuria/therapy , Cardiovascular Diseases/epidemiology , Albuminuria/classification , Albuminuria/epidemiology , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cardiovascular Diseases/mortality , Cardiovascular Diseases/prevention & control , Diagnosis, Differential , Glomerulonephritis/complications , Humans , Hypertension/drug therapy , Hypertension/prevention & control , Incidence , Prevalence , Renin-Angiotensin System/drug effects , Risk Factors
17.
Scand J Rheumatol ; 37(6): 401-9, 2008.
Article in English | MEDLINE | ID: mdl-18830904

ABSTRACT

OBJECTIVE: Growth differentiation factor-5 (GDF-5), a member of the transforming growth factor (TGF)-beta family, is involved in joint development during embryogenesis and has the potential to regenerate cartilage in adult animals. As progression of chronic joint diseases is influenced by cytokines of the synovial tissue, we examined the expression and effects of GDF-5 in this tissue. METHODS: Microarray experiments were investigated for differential expression of GDF-5 in synovial tissues, synovial fibroblasts, and peripheral blood cells. GDF-5 expression was validated by semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR), immunohistochemistry, double immunofluorescence, and in situ hybridization in synovial tissue of normal donors (ND) and patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Effects of inflammation and therapy were investigated in RA and OA fibroblasts after stimulation with interleukin (IL)-1beta, tumour necrosis factor (TNF)-alpha, methotrexate (MTX), and prednisolone. The influence of GDF-5 on macrophages was studied by chemotaxis assay. RESULTS: Microarray analysis and immunostaining revealed expression predominantly in synovial fibroblasts. Compared to patients without immunomodulating drugs, expression of GDF-5 was decreased significantly in patients receiving glucocorticoids and/or disease-modifying antirheumatic drugs (DMARDs) (p = 0.007), but did not differ between the total group of ND, OA, and RA. Stimulation with prednisolone and TNFalpha reduced GDF-5 expression in OA and RA fibroblasts, whereas MTX and IL-1beta revealed minor or no relevant change. GDF-5 also reduced cell migration of macrophages (p<0.001). CONCLUSION: GDF-5 is expressed in synovial fibroblasts and may counteract macrophage infiltration. Its modulation by inflammation and therapy suggests that glucocorticoids play a conflicting role by suppressing not only inflammation but also putative mechanisms of repair.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/metabolism , Glucocorticoids/therapeutic use , Growth Differentiation Factor 5/metabolism , Synovial Membrane/metabolism , Adult , Aged , Aged, 80 and over , Antirheumatic Agents/pharmacology , Arthritis, Rheumatoid/drug therapy , Case-Control Studies , Cell Migration Assays, Macrophage , Cytokines/pharmacology , Down-Regulation , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression , Glucocorticoids/pharmacology , Humans , Immunohistochemistry , Immunosuppression Therapy , In Situ Hybridization , Methotrexate/pharmacology , Methotrexate/therapeutic use , Middle Aged , Oligonucleotide Array Sequence Analysis , Prednisolone/pharmacology , Prednisolone/therapeutic use , Reverse Transcriptase Polymerase Chain Reaction , Synovial Membrane/drug effects , Tumor Necrosis Factor-alpha/pharmacology
18.
Eur J Clin Microbiol Infect Dis ; 27(6): 415-21, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18197444

ABSTRACT

It has been widely accepted that obesity is associated with chronic, low-grade inflammation that affects the adipose tissue as well as the entire system. The aim of this study was to assess whether past Chlamydia pneumoniae infection influences obesity phenotypes and serum levels of low-grade inflammation markers in obese, healthy premenopausal women. The study was performed on 48 obese and 42 normal-weight women, aged 31.2 +/- 7.2 years. Serum levels of C-reactive protein (CRP), tumor necrosis factor alpha (TNFalpha) and its soluble receptor R2 (sTNF-R2), and interleukin 6 (IL-6) were measured. Body composition was assessed by bioimpendance. Insulin sensitivity was assessed by quantitative insulin sensitivity check index (QUICKI). The seroprevalence of C. pneumoniae infection was 69.1% and was similar in obese and normal-weight women (75.2% and 61.9%, respectively; P = 0.18). Obese women had higher CRP than healthy controls (P < 0.05). IL-6, TNFalpha, and sTNF-R2 showed no significant differences when comparing obese and normal-weight or C. pneumoniae infected and uninfected women. In multivariate regression analysis, fat mass (P < 0.001) and QUICKI (P < 0.01), accounting for 35% of the variance of CRP and C. pneumoniae infection, did not significantly contribute to this model (P = 0.51). In conclusion, past C. pneumoniae infection was not associated with changes in chronic inflammation markers in premenopausal obese women.


Subject(s)
C-Reactive Protein/metabolism , Chlamydia Infections/complications , Inflammation/complications , Obesity , Biomarkers , Blood Glucose/metabolism , Body Mass Index , Body Weight/physiology , Chlamydia Infections/immunology , Chlamydophila pneumoniae/immunology , Chronic Disease , Female , Humans , Insulin Resistance , Obesity/blood , Obesity/microbiology , Obesity/physiopathology
19.
Transplant Proc ; 39(10): 3468-70, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18089410

ABSTRACT

Cinacalcet is a calcimimetic drug that has been approved for treatment of secondary and tertiary hyperparathyroidism in patients with renal failure requiring renal replacement therapy. A few cases of successful treatment in renal transplant patients immunosuppressed with cyclosporine have been reported. Herein we have reported the case of a 48-year-old renal transplant recipient presenting with secondary hypercalcemic hyperparathyroidism (parathyroid hormone [PTH] 896 pg/mL; total calcium, up to 3.3 mmol/L) under immunosuppressive therapy with tacrolimus. Owing to substantial comorbidity and a high operative risk, we decided to initiate a therapeutic trial with cinacalcet. Using a daily dose of 30 mg of Cinacalcet, normal calcium levels and a mild fall in PTH levels (decline of 62 pg/mL) were achieved within the first week of treatment. At this point, we also observed a marked decrease in tacrolimus levels (from 6.3 to 2.6 mg/dL) without any change in concomitant medications. Thus, we adapted the tacrolimus dosage. Concurrent with cinacalcet therapy, there was a rise in serum creatinine levels (from 3.9 to 4.9 mg/dL before discontinuation of cinacalcet), which was not reversible after termination of 3 weeks of treatment with cinacalcet, but continued. Cinacalcet and tacrolimus are both metabolized via cytochrome P 450. The documented decrease in tacrolimus serum levels, suggested a drug-drug interaction between tacrolimus and cinacalcet. The irreversible deterioration in renal function may be attributed to nephrotoxic properties of cinacalcet, but may also indicate an acceleration of the natural course of chronic allograft nephropathy.


Subject(s)
Creatinine/blood , Hyperparathyroidism, Secondary/blood , Hyperparathyroidism, Secondary/complications , Kidney Transplantation/adverse effects , Naphthalenes/therapeutic use , Tacrolimus/blood , Cinacalcet , Drug Interactions , Drug Therapy, Combination , Female , Humans , Hyperparathyroidism, Secondary/drug therapy , Immunosuppressive Agents/blood , Middle Aged
20.
Kidney Int ; 72(5): 599-607, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17579663

ABSTRACT

The inhibition of several chemokine/chemokine receptors has been shown to reduce progressive renal interstitial fibrosis. In this study, we examined the expression of the CX(3)C receptor in human renal biopsies with interstitial fibrosis and from normal kidneys by real-time polymerase chain reaction (PCR) and immunohistochemistry. The CX(3)C receptor was not only detected in mononuclear, tubular epithelial, and dendritic cells but also in alpha-smooth muscle actin and vimentin-positive interstitial myofibroblasts in fibrotic kidneys. Real-time PCR indicated a significant upregulation of CX(3)C receptor mRNA in fibrotic kidneys compared with non-fibrotic nephropathies or donor biopsies. In renal fibroblasts in vitro, hydrogen peroxide increased the expression of the CX(3)C receptor, an increase that was inhibited by N-acetylcysteine and catalase. However, neither proinflammatory nor profibrotic cytokines resulted in this upregulation. Stimulation of fibroblasts by CX(3)C ligand led to a significant enhancement of migration, which was abrogated by pre-incubation with a blocking anti-CX(3)C receptor antibody. Our studies indicate that renal fibrosis is associated with the expression of CX(3)C receptors on human renal fibroblasts. The expression is induced by reactive oxygen species suggesting a role of oxidative stress.


Subject(s)
Fibrosis/genetics , Kidney Diseases/genetics , Receptors, Cytokine/genetics , Receptors, HIV/genetics , CX3C Chemokine Receptor 1 , Fibroblasts/metabolism , Gene Expression , Humans , Immunohistochemistry , Polymerase Chain Reaction , Reactive Oxygen Species , Receptors, Cytokine/analysis , Receptors, HIV/analysis , Tissue Distribution , Up-Regulation/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...